HM100168 / Hanmi - LARVOL DELTA

A novel and potent IRE1α RNase inhibitor, HM100168 as a promising therapeutic strategy in solid cancers (AACR 2024) - "Also, co-targeting of IRE1α-XBP1 in combination with anti-tumorigenic agents can be considered a novel approach to overcome cancer resistance. Further preclinical studies will be performed and reported soon after the establishment of a preclinical candidate."

Brain Cancer • Breast Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Lung Adenocarcinoma • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ERN1 • XBP1